Nucleotide-Binding Oligomerization Domain (NOD)-Like Receptor Subfamily C (NLRC) As a Prognostic Biomarker for Glioblastoma Multiforme Linked to Tumor Microenvironment: A Bioinformatics, Immunohistochemistry, and Machine Learning-Based Study

Overview

Journal J Inflamm Res

Publisher Dove Medical Press

Date 2023 Feb 17

PMID 36798872

Authors

Shiyuan Han

Zimu Zhang

Wenbin Ma

Jun Gao

Yongning Li

Affiliations

Soon will be listed here.

Abstract

Purpose: Glioblastoma multiforme (GBM) remains the deadliest primary brain tumor. We aimed to illuminate the role of nucleotide-binding oligomerization domain (NOD)-like receptor subfamily C (NLRC) in GBM.

Patients And Methods: Based on public database data (mainly The Cancer Genome Atlas [TCGA]), we performed bioinformatics analysis to visually evaluate the role and mechanism of NLRCs in GBM. Then, we validated our findings in a glioma tissue microarray (TMA) by immunohistochemistry (IHC), and the prognostic value of NOD1 was assessed via random forest (RF) models.

Results: In GBM tissues, the expression of NLRC members was significantly increased, which was related to the low survival rate of GBM. Additionally, Cox regression analysis revealed that the expression of NOD1 (among NLRCs) served as an independent prognostic marker. A nomogram based on multivariate analysis proved the effective predictive performance of NOD1 in GBM. Enrichment analysis showed that high expression of NOD1 could regulate extracellular structure, cell adhesion, and immune response to promote tumor progression. Then, immune infiltration analysis showed that NOD1 overexpression correlated with an enhanced immune response. Then, in a glioma TMA, the results of IHC revealed that the increase in NOD1 expression indicated high recurrence and poor prognosis of human glioma. Furthermore, the expression level of NOD1 showed good prognostic value in the TMA cohort via RF.

Conclusion: The value of NOD1 as a biomarker for GBM was demonstrated. The possible mechanisms may lie in the regulatory role of NLRC-related pathways in the tumor microenvironment.

Citing Articles

Artificial Intelligence-Assisted Drug and Biomarker Discovery for Glioblastoma: A Scoping Review of the Literature.

Conte L, Caruso G, Philip A, Cucci F, De Nunzio G, Cascio D Cancers (Basel). 2025; 17(4).

PMID: 40002166 PMC: 11852502. DOI: 10.3390/cancers17040571.

Analysis of transcription profiles for the identification of master regulators as the key players in glioblastoma.

Ivanov S, Lagunin A, Tarasova O Comput Struct Biotechnol J. 2025; 23:3559-3574.

PMID: 39963421 PMC: 11832006. DOI: 10.1016/j.csbj.2024.09.022.

Advances on the therapeutic potential of cell receptor activation in glioblastoma.

Contreras-Chavez G, Zapi-Colin L, Contreras I, Estrada J Mol Biol Rep. 2025; 52(1):207.

PMID: 39907852 DOI: 10.1007/s11033-025-10312-w.

High expression of nucleotide-binding oligomerization domain protein 1 correlates with poor prognosis and immune cell infiltration in Glioblastoma Multiforme patients.

Zhao H, Lan B, Zhao Z, Zhu P, Wang C, Gao Y Discov Oncol. 2025; 16(1):32.

PMID: 39798050 PMC: 11724815. DOI: 10.1007/s12672-025-01786-y.

References

Lim J, Kim M, Park Y, Ahn J, Hwang S, Moon J . Upregulation of the NLRC4 inflammasome contributes to poor prognosis in glioma patients. Sci Rep. 2019; 9(1):7895. PMC: 6536517. DOI: 10.1038/s41598-019-44261-9. View

Kay C, Wang R, Kirkby M, Man S . Molecular mechanisms activating the NAIP-NLRC4 inflammasome: Implications in infectious disease, autoinflammation, and cancer. Immunol Rev. 2020; 297(1):67-82. DOI: 10.1111/imr.12906. View

Hu B, Elinav E, Huber S, Booth C, Strowig T, Jin C . Inflammation-induced tumorigenesis in the colon is regulated by caspase-1 and NLRC4. Proc Natl Acad Sci U S A. 2010; 107(50):21635-40. PMC: 3003083. DOI: 10.1073/pnas.1016814108. View

Bianconi A, Aruta G, Rizzo F, Salvati L, Zeppa P, Garbossa D . Systematic Review on Tumor Microenvironment in Glial Neoplasm: From Understanding Pathogenesis to Future Therapeutic Perspectives. Int J Mol Sci. 2022; 23(8). PMC: 9029619. DOI: 10.3390/ijms23084166. View

Lamano J, Lamano J, Li Y, DiDomenico J, Choy W, Veliceasa D . Glioblastoma-Derived IL6 Induces Immunosuppressive Peripheral Myeloid Cell PD-L1 and Promotes Tumor Growth. Clin Cancer Res. 2019; 25(12):3643-3657. PMC: 6571046. DOI: 10.1158/1078-0432.CCR-18-2402. View

Rashidi A, Miska J, Lee-Chang C, Kanojia D, Panek W, Lopez-Rosas A . GCN2 is essential for CD8 T cell survival and function in murine models of malignant glioma. Cancer Immunol Immunother. 2019; 69(1):81-94. PMC: 6952559. DOI: 10.1007/s00262-019-02441-6. View

Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf A . Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013; 39(4):782-95. DOI: 10.1016/j.immuni.2013.10.003. View

Velloso F, Sogayar M, Correa R . Expression and in vitro assessment of tumorigenicity for NOD1 and NOD2 receptors in breast cancer cell lines. BMC Res Notes. 2018; 11(1):222. PMC: 5883347. DOI: 10.1186/s13104-018-3335-4. View

Schulze Heuling E, Knab F, Radke J, Eskilsson E, Martinez-Ledesma E, Koch A . Prognostic Relevance of Tumor Purity and Interaction with MGMT Methylation in Glioblastoma. Mol Cancer Res. 2017; 15(5):532-540. DOI: 10.1158/1541-7786.MCR-16-0322. View

10.

Vo T, Nguyen N, Kha Q, Le N . On the road to explainable AI in drug-drug interactions prediction: A systematic review. Comput Struct Biotechnol J. 2022; 20:2112-2123. PMC: 9092071. DOI: 10.1016/j.csbj.2022.04.021. View

11.

Huang S, Song Z, Zhang T, He X, Huang K, Zhang Q . Identification of Immune Cell Infiltration and Immune-Related Genes in the Tumor Microenvironment of Glioblastomas. Front Immunol. 2020; 11:585034. PMC: 7606992. DOI: 10.3389/fimmu.2020.585034. View

12.

Lam L, Le N, Van Tuan L, Ban H, Hung T, Nguyen N . Machine Learning Model for Identifying Antioxidant Proteins Using Features Calculated from Primary Sequences. Biology (Basel). 2020; 9(10). PMC: 7599600. DOI: 10.3390/biology9100325. View

13.

Yang Y, Chu L, Zeng Z, Xu S, Yang H, Zhang X . Four specific biomarkers associated with the progression of glioblastoma multiforme in older adults identified using weighted gene co-expression network analysis. Bioengineered. 2021; 12(1):6643-6654. PMC: 8806527. DOI: 10.1080/21655979.2021.1975980. View

14.

Zhang B, Wu Q, Xu R, Hu X, Sun Y, Wang Q . The promising novel biomarkers and candidate small molecule drugs in lower-grade glioma: Evidence from bioinformatics analysis of high-throughput data. J Cell Biochem. 2019; 120(9):15106-15118. DOI: 10.1002/jcb.28773. View

15.

Batash R, Asna N, Schaffer P, Francis N, Schaffer M . Glioblastoma Multiforme, Diagnosis and Treatment; Recent Literature Review. Curr Med Chem. 2017; 24(27):3002-3009. DOI: 10.2174/0929867324666170516123206. View

16.

Saaid A, Monticelli M, Ricci A, Orlando G, Botta C, Zeppa P . Prognostic Analysis of the IDH1 G105G (rs11554137) SNP in IDH-Wildtype Glioblastoma. Genes (Basel). 2022; 13(8). PMC: 9408597. DOI: 10.3390/genes13081439. View

17.

Kai F, Drain A, Weaver V . The Extracellular Matrix Modulates the Metastatic Journey. Dev Cell. 2019; 49(3):332-346. PMC: 6527347. DOI: 10.1016/j.devcel.2019.03.026. View

18.

Jiang H, Najmeh S, Martel G, MacFadden-Murphy E, Farias R, Savage P . Activation of the pattern recognition receptor NOD1 augments colon cancer metastasis. Protein Cell. 2020; 11(3):187-201. PMC: 7026222. DOI: 10.1007/s13238-019-00687-5. View

19.

Bidou L, Bugaud O, Belakhov V, Baasov T, Namy O . Characterization of new-generation aminoglycoside promoting premature termination codon readthrough in cancer cells. RNA Biol. 2017; 14(3):378-388. PMC: 5367250. DOI: 10.1080/15476286.2017.1285480. View

20.

Petterson S, Sorensen M, Kristensen B . Expression Profiling of Primary and Recurrent Glioblastomas Reveals a Reduced Level of Pentraxin 3 in Recurrent Glioblastomas. J Neuropathol Exp Neurol. 2020; 79(9):975-985. DOI: 10.1093/jnen/nlaa088. View